Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Patients with available therapies known to confer clinical benefit (platinum sensitive recurrent ovarian cancer) must be excluded from the dose escalation portion

For the dose expansion cohort patients with first-recurrence platinum-sensitive ovarian cancer must be excluded

Patients who have had chemotherapy or radiotherapy within 4 weeks or five half-lives whichever is shorter (6 weeks for nitrosoureas or mitomycin C) prior to entering the study

Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual drug related toxicities \> grade 1) except for alopecia and grade 2 fatigue

Patients who are receiving any other investigational agents

Primary platinum refractory disease (disease progression on first platinum treatment or recurrence within 3 months of completing first platinum regimen)

Patients with clear cell or low grade ovarian cancer unless the patient has a known germline or somatic breast cancer (BRCA) mutation or a mutation in another homologous recombination gene

Any known gastrointestinal disorder determined by the investigator that interferes with the absorption of rucaparib

Symptomatic or uncontrolled brain metastases requiring concurrent treatment, inclusive of but not limited to surgery, radiation and/or corticosteroids; patients with treated brain metastases are eligible as long as they completed prior brain radiation therapy more than 14 days prior to first dose of study therapy, are not experiencing seizures and are not receiving steroids for symptomatic brain metastases (for at least 7 days prior to first dose of study treatment)

History of leptomeningeal carcinomatosis

Subjects with a known history of uncontrolled seizures

History of allergic reactions attributed to compounds of similar chemical or biologic composition to rucaparib, mirvetuximab soravtansine or monoclonal antibodies

Uncontrolled inter-current illness including, but not limited to:

* Ongoing or active infection (requiring IV antibiotics within 2 weeks of study enrollment)

* Symptomatic/uncontrolled congestive heart failure (New York heart association \> class II)

* Unstable angina pectoris

* Recent myocardial infarction (\< 6 months)

* Uncontrolled cardiac arrhythmia

* Uncontrolled hypertension (? Common Terminology Criteria for Adverse Events \[CTCAE\] v4.03 grade 3)

* Prior history of hypertensive crisis or hypertensive encephalopathy

* Hemorrhagic or ischemic stroke \< 6 months

* Clinically-significant vascular disease (e.g. aortic aneurysm, or dissecting aneurysm), severe aortic stenosis clinically significant peripheral vascular disease, or ? grade 3 cardiac toxicity following prior chemotherapy

* Interstitial lung disease (ILD)

* Active peptic ulcer disease or gastritis interfering with the absorption of rucaparib

* Active bleeding diatheses including any subject known to have evidence of acute or chronic hepatitis B, hepatitis C

* Active varicella zoster infection, cytomegalovirus infection, or history of tuberculosis

* Psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent

Active or chronic corneal disorder, including but not limited to the following: Sjogren?s syndrome, Fuchs corneal dystrophy (requiring treatment), history of corneal transplantation, active herpetic keratitis, and also active ocular conditions requiring on-going treatment/monitoring such as wet age-related macular degeneration requiring intravitreal injections, active diabetic retinopathy with macular edema, presence of papilledema, acquired monocular vision, and any preexisting active conjunctival disease

History of neurological conditions that would confound assessment of treatment-emergent neuropathy

History of multiple sclerosis or other demyelinating disease and/or Eaton-Lambert syndrome (para-neoplastic syndrome)

Previous clinical diagnosis of non-infectious pneumonitis

History or evidence of thrombotic disorders within 6 months before first study treatment unless stable on anticoagulation for \> 3 months

Required used of folate-containing supplements (e.g. folate deficiency)

Has a known additional malignancy that is progressing or required active treatment within 3 years of first dose of study treatment; exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy or other in situ cancers

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with rucaparib and mirvetuximab soravtansine

Women who are breastfeeding

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results

What this study is about